Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 79

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 1
Chunk 79
---
 In addition, animals treated with equivalent doses of BF-222
and BF-223 showed comparable and significant reduction in tumor growth compared to control animals during the study.

 16 

Competition

The
pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis
on proprietary products. The immuno-oncology, neuroscience, and rare disease segments of the industry in particular are highly competitive.
While we believe that our technology, development experience and scientific knowledge provide competitive advantages, we face potential
competition from many different sources, including major pharmaceutical, specialty pharmaceutical, and biotechnology companies, academic
institutions and governmental agencies, and public and private research institutions.

Many
of our competitors may have significantly greater financial resources, and expertise in research and development, manufacturing, preclinical
studies, conducting clinical trials, obtaining regulatory approvals, and marketing approved medicines than we do. Mergers and acquisitions
in the pharmaceutical, biotechnology, and diagnostic industries may result in even more resources being concentrated among a smaller
number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel
and in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary
to or necessary for our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large and established companies.

The
key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety,
convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, if any, the level of generic
competition and the availability of reimbursement from government and other third-party payors.

Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize medicines that are safer, are more
effective, have fewer or less severe side effects, are more convenient or are less expensive than any medicines we may develop. Our competitors
also may obtain FDA or other regulatory approval for their medicines more rapidly than we may obtain approval for ours, which could result
in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete
may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic medicines. There are many
generic medicines currently on the market for certain of the indications that we are pursuing, and additional generics are expected to
become